PDF(Pubmed)
Abstract：
Hypertension, a major health concern linked to heart disease and premature mortality, has prompted a search for alternative treatments due to side effects of existing medications. Sustainable harvesting of low-trophic marine organisms not only enhances food security but also provides a variety of bioactive molecules, including peptides. Despite comprising only a fraction of active natural compounds, peptides are ideal for drug development due to their size, stability, and resistance to degradation. Our review evaluates the anti-hypertensive properties of peptides and proteins derived from selected marine invertebrate phyla, examining the various methodologies used and their application in pharmaceuticals, supplements, and functional food. A considerable body of research exists on the anti-hypertensive effects of certain marine invertebrates, yet many species remain unexamined. The array of assessments methods, particularly for ACE inhibition, complicates the comparison of results. The dominance of in vitro and animal in vivo studies indicates a need for more clinical research in order to transition peptides into pharmaceuticals. Our findings lay the groundwork for further exploration of these promising marine invertebrates, emphasizing the need to balance scientific discovery and marine conservation for sustainable resource use.
摘要：
高血压,与心脏病和过早死亡有关的主要健康问题，由于现有药物的副作用，促使人们寻找替代疗法。低营养海洋生物的可持续收获不仅增强了粮食安全，而且还提供了多种生物活性分子，包括肽。尽管只包含一小部分活性天然化合物，由于其大小，肽是药物开发的理想选择，稳定性,和抗降解。我们的评论评估了来自选定的海洋无脊椎动物门的肽和蛋白质的抗高血压特性，检查所使用的各种方法及其在制药中的应用，补充剂,和功能性食品。关于某些海洋无脊椎动物的抗高血压作用的研究相当多，然而，许多物种仍未被检查。一系列的评估方法，特别是ACE抑制，使结果的比较复杂化。体外和动物体内研究的优势表明需要更多的临床研究以将肽转化为药物。我们的发现为进一步探索这些有前途的海洋无脊椎动物奠定了基础，强调需要平衡科学发现和海洋保护以实现可持续资源利用。
